FDA grants Orphan Drug Designation for small-molecule MM therapy
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for OPN-6602, an oral small-molecule EP300/CBP inhibitor, for patients with multiple
Multiple Myeloma
Lymphoma
FDA clears IND for novel relapsed or refractory NHL therapy
The US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LTZ-301, a first-in-class bispecific myeloid engager immunotherapy,
Cellular Therapy
Multiple Myeloma
Real-world study observes ‘superior’ outcomes with cilta-cel versus ide-cel for myeloma
A real-world study compared the two chimeric antigen receptor (CAR) T-cell therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for the treatment of
Cellular Therapy
Leukemia
Acute Lymphoblastic Leukemia
Meeting News
2025 Tandem Meetings
Deeper MRD response associated with better survival in obe-cel-treated patients with B-cell ALL
Measurable residual disease (MRD) negativity was associated with better response to treatment with the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) in
Lymphoma
Japan regulatory body approves epcoritamab for relapsed or refractory follicular lymphoma
The Japan Ministry of Health, Labour and Welfare has approved epcoritamab (Epkinly) as a treatment for adult patients with relapsed or refractory follicular
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Meeting News
2025 Tandem Meetings
Earlier administration of CAR-T treatment may improve survival in LBCL
Patients were randomized 1:1 to receive axi-cel (n=180) or SOC (n=179; chemotherapy followed by high-dose chemotherapy with autologous hematopoietic cell transplant for those
Roundtable Discussions
MPN Roundtable
What promising combination data exists on MPN treatments?
Which therapies in top-line data show potential benefits for anemia compared to expected levels with JAK inhibition.
Society Updates
Save the date: SOHO Spain 2025
SOHO will hold its first regional meeting in Spain from February 27-28, 2025, at the Rafael del Pino Auditorium in Madrid. The program
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Meetings / Conferences
2025 Tandem Meetings
Study questions clinical benefit of dexamethasone with axi-cel in LBCL patients
Prophylactic dexamethasone did not improve the safety or efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma (LBCL), according to a
Lymphoma
CAR-T treatment access, timeliness remain issues for patients with NHL
Researchers assessed barriers to chimeric antigen receptor (CAR) T-cell therapy for patients with non-Hodgkin lymphoma (NHL) in a community-based network and found that